Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Histone modifications silence the GATA transcription factor genes in ovarian cancer.

Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX.

Oncogene. 2006 Aug 31;25(39):5446-61. Epub 2006 Apr 10.

PMID:
16607277
2.

Epigenetic control of ovarian function: the emerging role of histone modifications.

LaVoie HA.

Mol Cell Endocrinol. 2005 Nov 24;243(1-2):12-8. Epub 2005 Oct 10. Review.

PMID:
16219412
3.

Epigenetic regulation of ARHI in breast and ovarian cancer cells.

Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC Jr.

Ann N Y Acad Sci. 2003 Mar;983:268-77. Review.

PMID:
12724231
4.

Epigenetic interplay between histone modifications and DNA methylation in gene silencing.

Vaissière T, Sawan C, Herceg Z.

Mutat Res. 2008 Jul-Aug;659(1-2):40-8. doi: 10.1016/j.mrrev.2008.02.004. Epub 2008 Feb 29. Review.

PMID:
18407786
5.

A methylation rendezvous: reader meets writers.

Brenner C, Fuks F.

Dev Cell. 2007 Jun;12(6):843-4. Review.

6.
7.

DNA methylation and histone modifications: teaming up to silence genes.

Fuks F.

Curr Opin Genet Dev. 2005 Oct;15(5):490-5. Review.

PMID:
16098738
8.

Aberrant epithelial differentiation in ovarian cancer.

Smith ER, Cai KQ, Capo-Chichi CD, Xu X.

Cancer Treat Res. 2009;149:147-63. doi: 10.1007/978-0-387-98094-2_7. Review. No abstract available.

PMID:
19763435
10.

Errors in erasure: links between histone lysine methylation removal and disease.

Duncan EM, Allis CD.

Prog Drug Res. 2011;67:69-90. Review.

PMID:
21141725
11.

Unravelling heterochromatin: competition between positive and negative factors regulates accessibility.

Dillon N, Festenstein R.

Trends Genet. 2002 May;18(5):252-8. Review.

PMID:
12047950
12.

Nickel carcinogenesis: epigenetics and hypoxia signaling.

Costa M, Davidson TL, Chen H, Ke Q, Zhang P, Yan Y, Huang C, Kluz T.

Mutat Res. 2005 Dec 30;592(1-2):79-88. Epub 2005 Jul 11. Review.

PMID:
16009382
13.

[Epigenetic regulation of histone H3 lysine 9 methylation in leukemia].

Zhao T, Ma XD.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Feb;20(1):210-3. Review. Chinese.

PMID:
22391199
14.

Modulation of gene expression in ovarian cancer by active and repressive histone marks.

Bapat SA.

Epigenomics. 2010 Feb;2(1):39-51. doi: 10.2217/epi.09.38. Review.

PMID:
22122747
15.

Combined targeting of the epigenetic silence in leukemia: cooperating activities of DNA methylation and histone deacetylation inhibitors.

Lübbert M.

Leuk Res. 2005 Jul;29(7):727-8. Epub 2005 Apr 26. Review. No abstract available.

PMID:
15927666
16.

Role of GATA factors in development, differentiation, and homeostasis of the small intestinal epithelium.

Aronson BE, Stapleton KA, Krasinski SD.

Am J Physiol Gastrointest Liver Physiol. 2014 Mar;306(6):G474-90. doi: 10.1152/ajpgi.00119.2013. Epub 2014 Jan 16. Review.

17.

[Post-transcriptional protein modification of Gata4].

Yu LW, Gui YH.

Zhongguo Dang Dai Er Ke Za Zhi. 2012 Oct;14(10):800-3. Review. Chinese.

PMID:
23092578
18.

Lysine methylation and 'signaling memory'.

Su IH, Tarakhovsky A.

Curr Opin Immunol. 2006 Apr;18(2):152-7. Epub 2006 Feb 7. Review.

PMID:
16464568
19.

Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.

Lai YC, Cheng CC, Lai YS, Liu YH.

Cancer Genomics Proteomics. 2017 Jul-Aug;14(4):219-223. Review.

20.

Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.

Marsh DJ, Shah JS, Cole AJ.

Front Oncol. 2014 Jun 12;4:144. doi: 10.3389/fonc.2014.00144. eCollection 2014. Review.

Supplemental Content

Support Center